日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment Consortium

可测量残留病灶(MRD)作为急性髓系白血病(AML)临床药物审批的替代终点:来自 MRD 合作组织和 AML 临床治疗联盟的观点

Boyiadzis, Michael; Wei, Andrew H; Paiva, Bruno; Freeman, Sylvie D; Kaspers, Gertjan; Chyla, Brenda; Hersey, Sarah; Patel, Reshma; Maloney, Brian; Blanchet Zumofen, Marie-Helene; Van Hoef, Marlies; Wulff, Beate; Obourn, Vanessa; Patel, Shalaka; Lopes de Menezes, Daniel; Shi, Qian; Bengoudifa, Bourras-Rezki; Dimier, Natalie; Prior, Thomas J; Roboz, Gail J; Prebet, Thomas

Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial

米哚妥林联合柔红霉素或伊达比星治疗FLT3突变型急性髓系白血病(AML)的年轻和老年患者:一项3b期试验

Sierra, Jorge; Montesinos, Pau; Thomas, Xavier; Griskevicius, Laimonas; Cluzeau, Thomas; Caillot, Denis; Legrand, Ollivier; Minotti, Clara; Luppi, Mario; Farkas, Firas; Bengoudifa, Bourras-Rezki; Gilotti, Geralyn; Hodzic, Sejla; Rambaldi, Alessandro; Venditti, Adriano

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

帕比司他联合硼替佐米和地塞米松治疗既往接受过治疗的多发性骨髓瘤:按既往治疗情况分析疗效

Richardson, Paul G; Hungria, Vânia T M; Yoon, Sung-Soo; Beksac, Meral; Dimopoulos, Meletios Athanasios; Elghandour, Ashraf; Jedrzejczak, Wieslaw W; Guenther, Andreas; Nakorn, Thanyaphong Na; Siritanaratkul, Noppadol; Schlossman, Robert L; Hou, Jian; Moreau, Philippe; Lonial, Sagar; Lee, Jae Hoon; Einsele, Hermann; Sopala, Monika; Bengoudifa, Bourras-Rezki; Corrado, Claudia; Binlich, Florence; San-Miguel, Jesús F